% | $
Quotes you view appear here for quick access.

Medivation, Inc. Message Board

  • berkelygenie berkelygenie Mar 7, 2013 1:57 PM Flag

    DNDN at $6.08 worth more than MDVN

    DNDN charges the same price for its drug with the same result, but DNDN owns 100% of its drug, not 50% like MDVN. DNDN doesn't have to give 10% of its profits to UCLA. DNDN has more applications of its drug and its revenues are nearly double MDVN. MDVN lost its patent battle with generation 2 Xtandi, called ARN509.
    ARN509 will be approved within a year and its doesn't cause seizures like Xtandi, and it is easier and cheaper to produce.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
81.440.00(0.00%)Sep 27 4:00 PMEDT